Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a recent randomized clinical ...

Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it could happen much sooner than later. The analysts pointed to ...